Phase 2 Head and Neck Cancer Trial, Recruiting NCT05491512 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT05491512
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with HPV-related squamous cell cancer of the oropharynx (such as the tonsil, base of tongue, or oropharyngeal walls), confirmed by a tissue or cell sample from a biopsy or surgery
  • Cancer of unknown origin in the neck may also qualify, if a lymph node biopsy has been done or the trial leaders approve (confirm with trial site)
  • You must have visible or measurable cancer present at the tumor site or nearby lymph nodes
  • There is no sign that the cancer has spread to distant parts of the body, based on a PET/CT scan
  • You have had a CT or MRI scan of the neck with and without contrast dye
  • You are generally well enough to carry out basic daily activities (your doctor can assess this using standard performance scales)
  • You are 18 years of age or older (note: those over 70 may only be eligible for a specific group within the trial)
  • Your blood counts are at acceptable levels, tested within the last 30 days (enough white blood cells, neutrophils, platelets, and hemoglobin)
  • Your kidneys are working well enough, based on a blood test taken within the last 30 days
  • Your liver is working well enough, based on blood tests taken within the last 30 days
  • If you are a woman who could become pregnant, you have had a negative pregnancy test within the last 14 days
  • You are willing and able to sign a consent form agreeing to take part in the study
  • You are able to have MRI scans, unless there is a strong medical reason you cannot (such as having a pacemaker), or the trial leaders approve an exception

Who may not be able to join:

  • You have previously had radiation therapy to the head or neck area
  • You currently have another active cancer outside of the oropharynx (though exceptions may be possible with trial leader approval)
  • You have had a different invasive cancer in the past, unless you have been cancer-free for at least 3 years, or the previous cancer had a very high cure rate (confirm with trial site)
  • You have previously received chemotherapy specifically for this oropharyngeal cancer (prior chemotherapy for a completely different cancer is acceptable)
  • You have serious unstable heart problems or heart failure that required a hospital stay in the last 6 months
  • You had a serious heart attack within the last 6 months
  • You currently have a serious bacterial or fungal infection being treated with intravenous antibiotics
  • You have had a serious flare-up of a lung condition, or another breathing problem, that required hospitalisation or would prevent you from receiving treatment within the last 30 days
  • You have serious liver failure causing yellowing of the skin or eyes, or problems with blood clotting

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nancy Lee, MD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-3341

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 August 2022
Est. completion
4 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with any locoregional recurrences

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov